An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer

Chest

Volumn 141, Issue 6, 2012, Pages 1466-1472

  Zhu, Xiao ^a,b   Lin, Marie C M ^c   Fan, Wenguo ^d,g   Tian, Linwei ^e   Wang, Jinlong ^b   Ng, Samuel S ^f   Wang, Min ^b   Kung, Hsiangfu ^e   Li, Dongpei ^g  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d SUN YAT SEN UNIVERSITY   (China)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

^g SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; GLUCOSE REGULATED PROTEIN 78; PLATINUM COMPLEX;

ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE REGULATED PROTEIN 78 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84862003614     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0469     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. (Pubitemid 40372904)
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350(4):379-392. (Pubitemid 38101633)
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
4. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94(3):173-181. (Pubitemid 34162751)
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98. (Pubitemid 34438899)
6. Tebbutt SJ, James A, Paré PD. Single-nucleotide polymorphisms and lung disease: clinical implications. Chest. 2007;131(4):1216-1223. (Pubitemid 46608727)
7. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009;59(1):42-55.
8. Girard N, Deshpande C, Azzoli CG, et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest. 2010;137(1):46-52.
9. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet. 2009;5(2):e1000337.
10. Fogli S, Caraglia M. Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives. Expert Opin Pharmacother. 2009;10(7):1095-1108.
11. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol. 2009;5(7):745-755.
12. Zhu X, Chen MS, Tian LW, et al. Single nucleotide polymorphism of rs430397 in the fifth intron of GRP78 gene and clinical relevance of primary hepatocellular carcinoma in Han Chinese: risk and prognosis. Int J Cancer. 2009;125(6):1352-1357.
13. Haas IG, Wabl M. Immunoglobulin heavy chain binding protein. Nature. 1983;306(5941):387-389. (Pubitemid 14242753)
14. Virrey JJ, Dong D, Stiles C, et al. Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res. 2008;6(8):1268-1275.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216.
16. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575. (Pubitemid 47330214)
17. West H, Harpole D, Travis W. Histologic considerations for indi vidualized systemic therapy approaches for the management of non-small cell lung cancer. Chest. 2009;136(4):1112-1118.
18. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations. 2000. Chest. 2009;136(suppl 5):e30.
19. Tomé S, Holt I, Edelmann W, et al. MSH2 ATPase domain mutation affects CTG*CAG repeat instability in transgenic mice. PLoS Genet. 2009;5(5):e1000482.
20. Hastings PJ, Bull HJ, Klump JR, Rosenberg SM. Adaptive amplification: an inducible chromosomal instability mechanism. Cell. 2000;103(5):723-731.
21. Little MP. Cancer models, genomic instability and somatic cellular Darwinian evolution. Biol Direct. 2010;5:19.
22. Pyrko P, Schönthal AH, Hofman FM, Chen TC, Lee AS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 2007;67(20):9809-9816. (Pubitemid 47621228)
23. Mohamed S, Yasufuku K, Nakajima T, et al. Analysis of cell cycle-related proteins in mediastinal lymph nodes of patients with N2-NSCLC obtained by EBUS-TBNA: relevance to chemotherapy response. Thorax. 2008;63(7):642-647. (Pubitemid 351969259)
24. Lee SM, James LE, Qian W, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax. 2009;64(1):75-80.
25. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 2009;15(1):9-14.
26. Lee E, Nichols P, Groshen S, Spicer D, Lee AS. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer. 2011;128(3):726-731.
27. Dong D, Ni M, Li J, et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008;68(2):498-505. (Pubitemid 351380077)
28. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle. 2006;5(22):2592-2601. (Pubitemid 44785803)
29. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med. 2006;6(1):45-54.
30. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007;67(8):3496-3499. (Pubitemid 46762126)
31. Zhang Y, Liu R, Ni M, Gill P, Lee AS. Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. J Biol Chem. 2010;285(20):15065-15075.
32. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002;38(3):217-227. (Pubitemid 35341796)
33. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov. 2010;9(5):363-366.
34. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS ONE. 2009;4(12):e7960.